IRIS
MARTINI, ALBERTO
 Distribuzione geografica
Salva come PNG Salva come JPEG
Continente #
EU - Europa 50.115
AS - Asia 4.899
NA - Nord America 3.814
Continente sconosciuto - Info sul continente non disponibili 572
SA - Sud America 366
AF - Africa 81
OC - Oceania 8
Totale 59.855
Salva come PNG Salva come JPEG
Nazione #
IT - Italia 49.239
US - Stati Uniti d'America 3.541
SG - Singapore 2.152
CN - Cina 1.174
VN - Vietnam 726
FR - Francia 437
BD - Bangladesh 385
BR - Brasile 222
HK - Hong Kong 154
FI - Finlandia 92
CA - Canada 87
DE - Germania 82
CH - Svizzera 77
MX - Messico 60
AR - Argentina 55
GB - Regno Unito 52
JP - Giappone 48
IN - India 41
JM - Giamaica 33
IQ - Iraq 29
ZA - Sudafrica 29
NL - Olanda 23
ID - Indonesia 22
EC - Ecuador 21
CO - Colombia 20
CR - Costa Rica 19
PH - Filippine 19
RU - Federazione Russa 19
TH - Thailandia 15
TR - Turchia 15
VE - Venezuela 15
CL - Cile 14
HN - Honduras 14
PK - Pakistan 14
GT - Guatemala 13
DZ - Algeria 12
IE - Irlanda 12
KR - Corea 12
JO - Giordania 11
ES - Italia 10
PR - Porto Rico 10
SV - El Salvador 10
KE - Kenya 9
MA - Marocco 9
PL - Polonia 9
PY - Paraguay 9
SE - Svezia 9
TW - Taiwan 9
NP - Nepal 8
RO - Romania 8
AT - Austria 7
KZ - Kazakistan 7
SA - Arabia Saudita 7
UA - Ucraina 7
AU - Australia 5
BY - Bielorussia 5
EG - Egitto 5
HR - Croazia 5
MY - Malesia 5
NI - Nicaragua 5
PE - Perù 5
AZ - Azerbaigian 4
LT - Lituania 4
OM - Oman 4
QA - Qatar 4
SY - Repubblica araba siriana 4
UZ - Uzbekistan 4
AE - Emirati Arabi Uniti 3
BB - Barbados 3
BS - Bahamas 3
IL - Israele 3
LB - Libano 3
MM - Myanmar 3
TT - Trinidad e Tobago 3
UY - Uruguay 3
AL - Albania 2
AM - Armenia 2
BO - Bolivia 2
CW - ???statistics.table.value.countryCode.CW??? 2
CY - Cipro 2
DO - Repubblica Dominicana 2
GA - Gabon 2
GM - Gambi 2
KH - Cambogia 2
MK - Macedonia 2
NO - Norvegia 2
NZ - Nuova Zelanda 2
PA - Panama 2
PS - Palestinian Territory 2
PT - Portogallo 2
RS - Serbia 2
SN - Senegal 2
TN - Tunisia 2
AD - Andorra 1
AG - Antigua e Barbuda 1
BA - Bosnia-Erzegovina 1
BE - Belgio 1
BG - Bulgaria 1
BM - Bermuda 1
BW - Botswana 1
Totale 59.259
Salva come PNG Salva come JPEG
Città #
Genova 32.756
Genoa 9.419
Rapallo 4.070
Vado Ligure 2.565
Singapore 1.038
San Jose 873
Ashburn 610
Lauterbourg 411
Ho Chi Minh City 206
Beijing 188
New York 185
Hanoi 167
Hong Kong 145
Santa Clara 108
Helsinki 88
Los Angeles 73
Zurich 72
Bordighera 65
Frankfurt am Main 61
Council Bluffs 59
Milan 45
Tokyo 44
Haiphong 38
Rome 37
Chicago 36
Mexico City 34
Buffalo 33
Dallas 31
Da Nang 28
Phoenix 26
Atlanta 22
Tianjin 22
Orem 21
Amsterdam 19
Kingston 19
Houston 18
Naples 18
São Paulo 16
Washington 16
City of London 15
Louisville 15
Seattle 15
Toronto 15
Brooklyn 14
San José 14
Baghdad 13
Charlotte 13
Montreal 13
Nuremberg 13
Princeton 13
Cardiff 12
Denver 12
Florence 12
Pasadena 12
Columbus 11
Dublin 11
Garland 11
Guangzhou 11
Johannesburg 11
San Francisco 11
Des Moines 10
Hải Dương 10
Newark 10
Philadelphia 10
San Salvador 10
Turin 10
Amman 9
Chennai 9
Guatemala City 9
Las Vegas 9
Biên Hòa 8
Guayaquil 8
Kansas City 8
Miami 8
Phủ Lý 8
Queens 8
Thái Nguyên 8
Bangkok 7
Bari 7
Jacksonville 7
Quito 7
Rio de Janeiro 7
Santiago 7
Shanghai 7
Ankara 6
Baltimore 6
Boardman 6
Boston 6
Can Tho 6
Cape Town 6
Durham 6
Jakarta 6
Leander 6
London 6
Long Xuyen 6
Manlius 6
Memphis 6
Monroe 6
Nairobi 6
New Delhi 6
Totale 54.246
Salva come PNG Salva come JPEG
Nome #
Relationship between damage accrual, disease flares and cumulative drug therapies in juvenile-onset systemic lupus erythematosus. 273
Novel automated system for Magnetic Resonance Imaging quantification of the inflamed synovial membrane volume in patients with juvenile idiopathic arthritis. 271
CD70 deficiency due to a novel mutation in a patient with severe chronic EBV infection presenting as a periodic fever 252
A longitudinal printo study on growth and puberty in juvenile systemic lupus erythematosus. 240
ADA2 deficiency (DADA2) as an unrecognised cause of early onset polyarteritis nodosa and stroke: a multicentre national study 238
A Meta-Analysis to Estimate the Placebo Effect in Randomized Controlled Trials in Juvenile Idiopathic Arthritis 216
Expert consensus on dynamics of laboratory tests for diagnosis of macrophage activation syndrome complicating systemic juvenile idiopathic arthritis 215
Malattia di Menetrier e gastropatia ipertrofica proteino-disperdente transitoria del bambino: due entità cliniche distinte? 214
Delineating the application of ultrasound in detecting synovial abnormalities of subtalar joint in juvenile idiopathic arthritis 211
HRCT and pulmonary function tests in monitoring of lung involvement in juvenile systemic sclerosis. 210
Multi-antibody composition in lupus nephritis: Isotype and antigen specificity make the difference 207
Remission, minimal disease activity, and acceptable symptom state in juvenile idiopathic arthritis: Defining criteria based on the juvenile arthritis disease activity score 206
Development and validation of a composite disease activity score for juvenile idiopathic arthritis 205
Development and Initial Validation of the Macrophage Activation Syndrome/Primary Hemophagocytic Lymphohistiocytosis Score, a Diagnostic Tool that Differentiates Primary Hemophagocytic Lymphohistiocytosis from Macrophage Activation Syndrome 205
Cross-cultural adaptation and psychometric evaluation of the Juvenile Arthritis Multidimensional Assessment Report (JAMAR) in 54 languages across 52 countries: review of the general methodology 202
Genetic architecture distinguishes systemic juvenile idiopathic arthritis from other forms of juvenile idiopathic arthritis: Clinical and therapeutic implications 202
A proposal for a pediatric version of the Systemic Lupus International Collaborating Clinics/American College of Rheumatology Damage Index based on the analysis of 1,015 patients with juvenile-onset systemic lupus erythematosus. 201
Parent and child acceptable symptom state in juvenile idiopathic arthritis. 201
MRI versus conventional measures of disease activity and structural damage in evaluating treatment efficacy in juvenile idiopathic arthritis. 201
2016 Classification criteria for macrophage activation syndrome complicating systemic juvenile idiopathic arthritis: A European league against Rheumatism/American college of Rheumatology/Paediatric rheumatology international trials organisation collaborative initiative 201
Candidate Genes in Patients with Autoinflammatory Syndrome Resembling Tumor Necrosis Factor Receptor-associated Periodic Syndrome Without Mutations in the TNFRSF1A Gene 199
The Croatian version of the Juvenile Arthritis Multidimensional Assessment Report (JAMAR) 199

Dynamic Contrast-Enhanced Magnetic Resonance Imaging in Assessment of Disease Activity in Patients with Juvenile Idiopathic Arthritis 197
The EULAR/PRINTO/PRES criteria for Henoch-Schönlein purpura, childhood polyarteritis nodosa, childhood Wegener granulomatosis, and childhood Takayasu arteritis: ankara 2008. part ii: final classification criteria. 197
Whole-body MRI in the assessment of disease activity in juvenile dermatomyositis 194
Assessment of damage in juvenile-onset systemic lupus erythematosus: a multicenter cohort study. 192
Intra-articular corticosteroids versus intra-articular corticosteroids plus methotrexate in oligoarticular juvenile idiopathic arthritis: a multicentre, prospective, randomised, open-label trial 192
2016 ACR-EULAR adult dermatomyositis and polymyositis and juvenile dermatomyositis response criteria-methodological aspects 192
The Italian version of the Juvenile Arthritis Multidimensional Assessment Report (JAMAR) 191
HLA-DRB1∗11 and variants of the MHC class II locus are strong risk factors for systemic juvenile idiopathic arthritis 191
Interferon-γ-dependent inhibition of B cell activation by bone marrow-derived mesenchymal stem cells in a murine model of systemic lupus erythematosus. 191
A randomized, placebo-controlled trial of infliximab plus methotrexate for the treatment of polyarticular-course juvenile rheumatoid arthritis 190
Abatacept in children with juvenile idiopathic arthritis: a randomised, double-blind, placebo-controlled withdrawal trial. 189
Discordance between proxy-reported and observed assessment of functional ability of children with juvenile idiopathic arthritis. 188
A circulating reservoir of pathogenic-like CD4+ T cells shares a genetic and phenotypic signature with the inflamed synovial micro-environment 188
A positive family history of psoriasis does not affect the clinical expression and course of juvenile idiopathic arthritis patients with oligoarthritis. 187
Differentiating PFAPA syndrome from monogenic periodic fevers. 185
Agreement among musculoskeletal pediatric specialists in the assessment of radiographic joint damage in juvenile idiopathic arthritis. 185
Dissecting the heterogeneity of macrophage activation syndrome complicating systemic juvenile idiopathic arthritis 185
Therapeutic approaches in the treatment of juvenile dermatomyositis in patients with recent-onset disease and in those experiencing disease flare: an international multicenter PRINTO study 185
Advances in biomarkers for paediatric rheumatic diseases 183
A phase II, multicenter, open-label study evaluating dosing and preliminary safety and efficacy of canakinumab in systemic juvenile idiopathic arthritis with active systemic features. 182
Disease status, reasons for discontinuation and adverse events in 1038 Italian children with juvenile idiopathic arthritis treated with etanercept 182
Agreement between physicians and parents in rating functional ability of children with juvenile idiopathic arthritis. 177
A New Approach to Clinical Care of Juvenile Idiopathic Arthritis: The Juvenile Arthritis Multidimensional Assessment Report 177
Development and initial validation of the MS score for diagnosis of macrophage activation syndrome in systemic juvenile idiopathic arthritis 177
Next-generation sequencing and its initial applications for molecular diagnosis of systemic auto-inflammatory diseases 176
2011 American College of Rheumatology recommendations for the treatment of juvenile idiopathic arthritis: initiation and safety monitoring of therapeutic agents for the treatment of arthritis and systemic features 175
Self epitopes shared between human skeletal myosin and Streptococcus pyogenes M5 protein are targets of immune responses in active juvenile dermatomyositis. 174
Cryopyrin-associated periodic syndromes in Italian Patients: Evaluation of the rate of somatic NLRP3 mosaicism and phenotypic characterization 174
The role of imaging in juvenile idiopathic arthritis 174
Development and validation of a composite disease activity score for measurement of muscle and skin involvement in juvenile dermatomyositis 174
Neurological disorders, other than stroke, associated with antiphospholipid antibodies in childhood. 173
Preliminary definition of improvement in juvenile arthritis. 172
Clinical features, treatment, and outcome of macrophage activation syndrome complicating systemic juvenile idiopathic arthritis: a multinational, multicenter study of 362 patients. 172
2016 Classification Criteria for Macrophage Activation Syndrome Complicating Systemic Juvenile Idiopathic Arthritis: A European League Against Rheumatism/American College of Rheumatology/Paediatric Rheumatology International Trials Organisation Collaborative Initiative 172
Development and testing of a hybrid measure of muscle strength in juvenile dermatomyositis for use in routine care 172
Phenotypic and functional characterisation of CCR7+ and CCR7- CD4+ memory T cells homing to the joints in juvenile idiopathic arthritis. 170
Aortic valve regurgitation as the presenting sign of Takayasu arteritis. 169
EULAR-PReS points to consider for the use of imaging in the diagnosis and management of juvenile idiopathic arthritis in clinical practice 169
Early changes in gene expression and inflammatory proteins in systemic juvenile idiopathic arthritis patients on canakinumab therapy 168
Preliminary core sets of measures for disease activity and damage assessment in juvenile systemic lupus erythematosus and juvenile dermatomyositis. 167
Prevalence of anticardiolipin antibodies in juvenile chronic arthritis. 167
An international consensus survey of diagnostic criteria for macrophage activation syndrome in systemic juvenile idiopathic arthritis 166
Antiphospholipid antibody syndrome in pediatric patients. 166
A web-based collection of genotype-phenotype associations in hereditary recurrent fevers from the Eurofever registry 166
Achievement of a state of inactive disease at least once in the first 5 years predicts better outcome of patients with polyarticular juvenile idiopathic arthritis. 165
Outcome and predicting factors of single and multiple intra-articular corticosteroid injections in children with juvenile idiopathic arthritis 165
Radiologic progression in patients with juvenile chronic arthritis treated with methotrexate. 165
Relative responsiveness of condition specific and generic health status measures in juvenile idiopathic arthritis. 165
Hypocomplementemic urticarial vasculitis syndrome with severe systemic manifestations 165
Development and initial validation of composite parent and child centered disease assessment indices for juvenile idiopathic arthritis. 165
A diagnostic score for molecular analysis of hereditary autoinflammatory syndromes with periodic fever in children 164
Evaluation of 21-Numbered Circle and 10-Centimeter Horizontal Line Visual Analog Scales for Physician and Parent Subjective Ratings in Juvenile Idiopathic Arthritis 164
Prednisone versus prednisone plus ciclosporin versus prednisone plus methotrexate in new-onset juvenile dermatomyositis: A randomised trial 164
Paediatric-onset systemic lupus erythematosus. 164
Bone marrow-derived mesenchymal stem cells induce both polyclonal expansion and differentiation of B cells isolated from healthy donors and systemic lupus erythematosus patients 164
Efficacy and safety of tocilizumab in patients with polyarticular-course juvenile idiopathic arthritis: results from a phase 3, randomised, double-blind withdrawal trial. 164
The PRINTO evidence-based proposal for glucocorticoids tapering/discontinuation in new onset juvenile dermatomyositis patients 163
Health-related quality of life in juvenile-onset systemic lupus erythematosus and its relationship to disease activity and damage. 162
In vivo neutralization of human IL-6 (hIL-6) achieved by immunization of hIL-6 transgenic mice with a hIL-6 receptor antagonist 162
Antinuclear antibody positive patients should be grouped as a separate category in the classification of juvenile idiopathic arthritis. 162
Criteria to define response to therapy in paediatric rheumatic diseases. 162
Performance of different diagnostic criteria for familial Mediterranean fever in children with periodic fevers: Results from a multicenter international registry 161
Preliminary diagnostic guidelines for macrophage activation syndrome complicating systemic juvenile idiopathic arthritis. 160
Seeking insights into the EPidemiology, treatment and Outcome of Childhood Arthritis through a multinational collaborative effort: Introduction of the EPOCA study. 160
Factors associated with achievement of inactive disease in children with juvenile idiopathic arthritis treated with etanercept. 160
Therapeutic approaches for the treatment of renal disease in juvenile systemic lupus erythematosus: an international multicentre PRINTO study. 160
Phenotypic variability and disparities in treatment and outcomes of childhood arthritis throughout the world: an observational cohort study 160
Performing trials in children with rheumatic diseases: Comment on the editorial by Lehman 159
A new short and simple health-related quality of life measure for paediatric rheumatic diseases: initial validation in juvenile idiopathic arthritis 159
The pattern of response to anti-interleukin-1 treatment distinguishes two subsets of patients with systemic-onset juvenile idiopathic arthritis. 159
A randomized, double-blind, placebo-controlled trial of paracetamol and ketoprofren lysine salt for pain control in children with pharyngotonsillitis cared by family pediatricians 159
Abatacept improves health-related quality of life, pain, sleep quality, and daily participation in subjects with juvenile idiopathic arthritis 159
Marked and sustained improvement 2 years after autologous stem cell transplantation in a girl with systemic sclerosis. 159
Pharmacovigilance in juvenile idiopathic arthritis patients treated with biologic or synthetic drugs: combined data of more than 15,000 patients from Pharmachild and national registries 158
High prevalence of antiphospholipid antibodies in children with idiopatic cerebral ischemia 157
Factors associated with response to methotrexate in systemic-onset juvenile chronic arthritis. 157
Defective iron supply for erythropoiesis and adequate endogenous erythropoietin production in the anemia associated with systemic-onset juvenile chronic arthritis. 157
The PRINTO criteria for clinically inactive disease in juvenile dermatomyositis. 157
Totale 18.168
Salva come PNG Salva come JPEG
Categoria #
all - tutte 192.698
article - articoli 190.247
book - libri 0
conference - conferenze 333
curatela - curatele 0
other - altro 0
patent - brevetti 0
selected - selezionate 0
volume - volumi 2.118
Totale 385.396
Salva come PNG Salva come JPEG


Totale Lug Ago Sett Ott Nov Dic Gen Feb Mar Apr Mag Giu
2021/20225.601 169 427 630 448 324 238 441 1.286 206 452 330 650
2022/20234.939 549 243 44 419 844 976 23 467 919 32 345 78
2023/20242.124 147 372 45 210 197 345 117 133 96 53 105 304
2024/20256.158 98 573 247 384 816 673 543 875 310 360 497 782
2025/202611.998 1.199 403 623 924 1.533 1.360 2.026 552 850 1.179 690 659
2026/20271.316 1.316 0 0 0 0 0 0 0 0 0 0 0
Totale 59.855